trial · primary record
Durvalumab
Urinary Bladder Neoplasms
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2022-10-17 |
| Primary endpoint | Number of Grades 1-5 Adverse Events |
| Registry ID | NCT03258593 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:45.414Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03258593
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.